

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI695191

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Charles River Laboratories, Inc.	12/13/2024
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	JPMorgan Chase Bank, N.A., as Administrative Agent
<b>Street Address:</b>	10 S. Dearborn
<b>Internal Address:</b>	Floor L2N
<b>City:</b>	Chicago
<b>State/Country:</b>	ILLINOIS
<b>Postal Code:</b>	60603
<b>PROPERTY NUMBERS Total: 63</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	7329538
Patent Number:	7939291
Patent Number:	10119969
Patent Number:	8440394
Patent Number:	7901899
Patent Number:	11221335
Patent Number:	10473663
Patent Number:	10473664
Patent Number:	D667417
Patent Number:	D667022
Patent Number:	D667418
Patent Number:	8993260
Patent Number:	8993259
Patent Number:	D782694
Patent Number:	D759836
Patent Number:	D776295
Patent Number:	D717464
Patent Number:	9624463
Patent Number:	11124581

PATENT

Property Type	Number
Patent Number:	D831223
Patent Number:	D821604
Patent Number:	D859488
Patent Number:	D829340
Patent Number:	D821605
Patent Number:	D829338
Patent Number:	12156894
Patent Number:	12158471
Patent Number:	10125198
Patent Number:	10557149
Patent Number:	10653731
Patent Number:	10801042
Patent Number:	11001859
Patent Number:	11129890
Patent Number:	D717462
Patent Number:	D717463
Patent Number:	D724755
Patent Number:	D759837
Patent Number:	11685773
Patent Number:	9709500
Patent Number:	10976258
Patent Number:	D698939
Patent Number:	D704854
Patent Number:	D705438
Patent Number:	D705439
Patent Number:	D719666
Patent Number:	D728816
Patent Number:	D776296
Patent Number:	D726929
Application Number:	17404545
Application Number:	17627162
Application Number:	17627170
Application Number:	17685881
Application Number:	17938727
Application Number:	29868937
Application Number:	63506271
Application Number:	63513528
Application Number:	18275777

Property Type	Number
Application Number:	18487284
Application Number:	18479401
Application Number:	18397630
Application Number:	18771040
Application Number:	18904606
Application Number:	18593114

**CORRESPONDENCE DATA**

Fax Number: 2124552502

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: (212)455-2592

Email: jnull@stblaw.com

Correspondent Name: Courtney Welshimer

Address Line 1: 425 Lexington Avenue

Address Line 4: New York, NEW YORK 10017

ATTORNEY DOCKET NUMBER:	509265/1062
NAME OF SUBMITTER:	JASON MULL
SIGNATURE:	JASON MULL
DATE SIGNED:	12/13/2024

**Total Attachments: 7**

source=CRL - Patent Security Agreement Short Form (CRL, Inc.) [Executed]#page1.tiff

source=CRL - Patent Security Agreement Short Form (CRL, Inc.) [Executed]#page2.tiff

source=CRL - Patent Security Agreement Short Form (CRL, Inc.) [Executed]#page3.tiff

source=CRL - Patent Security Agreement Short Form (CRL, Inc.) [Executed]#page4.tiff

source=CRL - Patent Security Agreement Short Form (CRL, Inc.) [Executed]#page5.tiff

source=CRL - Patent Security Agreement Short Form (CRL, Inc.) [Executed]#page6.tiff

source=CRL - Patent Security Agreement Short Form (CRL, Inc.) [Executed]#page7.tiff

GRANT OF  
SECURITY INTEREST IN PATENT RIGHTS

THIS GRANT OF SECURITY INTEREST IN PATENT RIGHTS (“Agreement”), effective as of December 13, 2024 is made by Charles River Laboratories, Inc., a corporation formed under the laws of Delaware (the “Obligor”), in favor of JPMorgan Chase Bank, N.A., as Administrative Agent (the “Agent”) for the several banks and other financial institutions (the “Lenders”), parties to the Tenth Amended and Restated Credit Agreement, dated as of the date hereof (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among Charles River Laboratories International, Inc., a Delaware corporation and parent of Obligor (“Parent Borrower”), certain Subsidiaries of the Parent Borrower, the Lenders and the Agent.

W I T N E S S E T H:

WHEREAS, pursuant to the Credit Agreement, the Lenders have severally agreed to make Loans and other extensions of credit to the Parent Borrower upon the terms and subject to the conditions set forth therein; and

WHEREAS, in connection with the Credit Agreement, the Obligor and the Parent Borrower have executed and delivered a Tenth Amended and Restated Security Agreement, dated as of the date hereof, in favor of the Agent (together with all amendments, restatements, amendments and restatements, supplements and other modifications, if any, from time to time thereafter made thereto, the “Security Agreement”);

WHEREAS, pursuant to the Security Agreement, Obligor pledged and granted to the Agent for the benefit of the Agent and the Lenders a continuing security interest in all Intellectual Property, including the Patents; and

WHEREAS, Obligor has duly authorized the execution, delivery and performance of this Agreement.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and in order to induce the Lenders to make Loans and other financial accommodations to the Parent Borrower pursuant to the Credit Agreement, Obligor agrees, for the benefit of the Agent and the Lenders, as follows:

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided or provided by reference in the Credit Agreement or the Security Agreement, as applicable.

SECTION 2. Grant of Security Interest. Obligor hereby grants, mortgages, pledges, hypothecates and transfers to the Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, and hereby grants to the Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, a continuing security interest in all of the Obligor’s right, title and interest in the Patents (including, without limitation, those items listed on Schedule A hereto, which includes all of the Obligor’s Patents for which a grant of security interest in patent rights agreement in favor of the Administrative Agent has not previously been filed with

the United States Patent and Trademark Office), as security for the payment and performance in full of the Obligations.

SECTION 3. Purpose. This Agreement has been executed and delivered by Obligor for the purpose of recording the grant of security interest herein with the United States Patent and Trademark Office. The security interest granted hereby has been granted to the Lenders in connection with the Security Agreement and is expressly subject to the terms and conditions thereof. The Security Agreement (and all rights and remedies of the Lenders thereunder) shall remain in full force and effect in accordance with its terms.

SECTION 4. Acknowledgment. Obligor does hereby further acknowledge and affirm that the rights and remedies of the Lenders with respect to the security interest in the Patents granted hereby are more fully set forth in the Credit Agreement and the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.

SECTION 5. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute a single contract.

SECTION 6. Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the day and year first above written.

CHARLES RIVER LABORATORIES, INC.

By: Flavia Pease  
Name: Flavia H. Pease  
Title: Corporate Executive Vice President  
and CFO

[Charles River Patent Security Agreement]

#99564041v1

**PATENT**  
**REEL: 069647 FRAME: 0930**

JPMORGAN CHASE BANK, N.A.  
as Administrative Agent for the Lenders

By: William R. Doolittle  
Name: William R. Doolittle  
Title: Executive Director

[Charles River Patent Security Agreement]

**PATENT**  
**REEL: 069647 FRAME: 0931**

## SCHEDULE A

### U.S. Patent Registrations

<u>Patent No.</u>	<u>Title</u>	<u>Country</u>
7,329,538	Methods And Compositions for The Detection of Microbial Contaminants	US
7,939,291	Methods for the Detection of Microbial Contaminants	US
10,119,969	Compositions for the Detection of Microbial Contaminants	US
8,440,394	Methods for the Detection and/or Quantification of Gram Positive Bacterial Contaminants	US
7,901,899	Method for Classifying a Microorganism in a Biological Sample	US
11,221,335	Heat-Treated Limulus Amebocyte Lysates	US
10,473,663	Heat-Treated Limulus Amebocyte Lysates	US
10,473,664	Heat-Treated Limulus Amebocyte Lysates	US
D667,417	User Interface for a Computer Display	US
D667,022	Computer Display with a Graphical User Interface	US
D667,418	Computer Display with a Graphical User Interface	US
8,993,260	Fluorescence-Based Viability Staining Method Using a Membrane Permeable Fluorescent Dye and Membrane Impermeable Fluorescence Quencher	US
8,993,259	Method Of Viability Staining with Membrane Permeable Fluorescent Dye and Membrane Impermeable Fluorescence Quencher	US
D782,694	Filtration Device	US
D759,836	Cup	US
D776,295	Base	US
D717,464	Base Assembly	US
9,624,463	Filtration System and Use Thereof	US
11,124,581	Method for Mass Humanization of Non-Human Antibodies	US
D831,223	Filtration System	US
D821,604	Blister	US
D859,488	Ringed Membrane	US
D829,340	Depressor	US
D821,605	Scanning Device Adapter	US
D829,338	Membrane Holder	US
12,156,894	Recombinantly-Modified Adeno-Associated Virus (rAAV) having Improved Packaging Efficiency	US
12,158,471	Recombinant amebocyte lysate and uses thereof	US
10,125,198	METHOD FOR MASS HUMANIZATION OF NON-HUMAN ANTIBODIES	US
10,557,149	RECOMBINANTLY-MODIFIED ADENO-ASSOCIATED VIRUS HELPER VECTORS AND THEIR USE TO IMPROVE THE	US

<b><u>Patent No.</u></b>	<b><u>Title</u></b>	<b><u>Country</u></b>
	PACKAGING EFFICIENCY OF RECOMBINANTLY-MODIFIED ADENO-ASSOCIATED VIRUS	
10,653,731	Recombinantly-Modified Adeno-Associated Virus (rAAV) Having Improved Packaging Efficiency	US
10,801,042	Use of Ion Concentrations to Increase the Packaging Efficiency of Recombinant Adeno-Associated Virus	US
11,001,859	Recombinantly-Modified Adeno-Associated Virus Helper Vectors and Their Use to Improve the Packaging Efficiency of Recombinantly-Modified Adeno-Associated Virus	US
11,129,890	NON-INTEGRATING HIV-1 COMPRISING MUTANT RT/IN PROTEINS AND PSEUDOTYPED WITH SARS-COV-2 SPIKE PROTEIN	US
D717,462	Cell capture system	US
D717,463	Base	US
D724,755	Cup	US
D759,837	Cup	US
11,685,773	Method for mass humanization of rabbit antibodies	US
9,709,500	Optical method for detecting viable microorganisms in a cell sample <sup>1</sup>	US
10,976,258	Porous planar cell capture system and method of use*	US
D698,939	Lid*	US
D704,854	Stage*	US
D705,438	Base*	US
D705,439	Base with membrane and support*	US
D719,666	CELL DETECTION SYSTEM WITH TOUCHSCREEN*	US
D728,816	Cup*	US
D776,296	Adapter*	US
D726,929	Cup assembly*	US

---

<sup>1</sup> This and other patents marked with an asterisk ("\*") are jointly owned with RealMetrix, Inc.

## U.S. Patent Applications

<u>Application No.</u>	<u>Title</u>	<u>Country</u>
17/404,545	Method for Mass Humanization of Non-Human Antibodies	US
17/627,162	Use of Ion Concentrations to Increase the Packaging Efficiency of Recombinant Adeno-Associated Virus	US
17/627,170	Recombinantly-Modified Adeno-Associated Virus Helper Vectors and Their Use to Improve the Packaging Efficiency of Recombinantly-Modified Adeno-Associated Virus	US
17/685,881	Methods of Antibody Panning against Target Proteins	US
17/938,727	Polyethylene Glycol Conjugates of Polyethyleneimine and Their Use in Gene Therapy	US
29/868,937	Cartridge Dispenser	US
63/506,271	Recombinant Amebocyte Clotting Factors and Uses Thereof	US
63/513,528	Spectrophotometers and Related Methods	US
18/275,777	Hybrid Amebocyte Lysate and Uses Thereof	US
18/487,284	Automated Enumeration System	US
18/479,401	Radically Diverse Human Antibody Library	US
18/397,630	Customer Access Management System and Method	US
18/771,040	Spectrophotometers and Related Methods	US
18/904,606	Articles and Methods Involving Detection of Binding	US
18/593,114	Method for Improving Genetic Engineering of Adoptive Cell Therapies	US